On August 15, 2019 NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), reported that the previously announced capital increase of €1 million through a private placement of shares without warrants (see press release of August 6, 2019) has been completed and that further investment is already committed for a future investment round (Press release, NOXXON, AUG 15, 2019, View Source [SID1234538786]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce the completion of the capital increase, which has placed NOXXON in a solid position that will facilitate the advancement and initiation of the Phase 1/2 clinical trial in brain cancer. We are working at full speed to open the clinical trial sites in Germany where the trial has already been approved by the regulatory authorities and Ethics Committees. In parallel, we are in active discussions regarding additional financing, industry partnerships and M&A," said Aram Mangasarian, CEO of NOXXON.